Home › NDC Lookup › RxCUI directory › RxCUI 1490473

Tasimelteon 20 MG Oral Capsule — RxCUI 1490473

RxNorm drug concept · Semantic clinical drug
RxCUI 1490473 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1490473
Official nameTasimelteon 20 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped7
Reported Medicaid activity (SDUD)1,179 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tasimelteon: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That's a really common question, and the honest answer is: it varies. Because everyone's internal body clock runs a little differently, some people notice improvement within a few...
  • How long will it take before I actually start sleeping better?
  • You'll want to time your meal carefully. Eating — especially a high-fat meal — can significantly reduce how much tasimelteon your body actually absorbs, and it delays how quickly t...
  • Drowsiness is a known effect of tasimelteon, which is actually intentional — it's helping shift your sleep timing. The main advice is to take it and then head straight to bed; don'...
📖 Read our full Tasimelteon guide →

🕸️ Concept Web — How Tasimelteon 20 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tasimelteon 20 MG Oral Capsule RxCUI 1490473

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tasimelteon 1490468
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Hetlioz 1491619
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tasimelteon Oral Capsule 1490472
    • Tasimelteon Oral Product 1490470
    • Tasimelteon Pill 1490471
    • Tasimelteon Oral Capsule [Hetlioz] 1491621
    • Hetlioz Oral Product 1491622
    • Hetlioz Pill 1491623
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tasimelteon 20 MG SCDC · 1490469
  • Tasimelteon Oral Capsule SCDF · 1490472
  • Tasimelteon Oral Product SCDG · 1490470
  • Tasimelteon Pill SCDG · 1490471

Brand-Name Concepts

  • Tasimelteon 20 MG Oral Capsule [Hetlioz] SBD · 1491624
  • Tasimelteon 20 MG [Hetlioz] SBDC · 1491620
  • Tasimelteon Oral Capsule [Hetlioz] SBDF · 1491621
  • Hetlioz Oral Product SBDG · 1491622
  • Hetlioz Pill SBDG · 1491623
  • Hetlioz BN · 1491619

📦 FDA Products & Package NDCs

5 products · 7 package NDCs
7 package NDCs map to RxCUI 1490473 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00480-4490-56 30 CAPSULE, GELATIN COATED in 1 BOTTLE (0480-4490-56) Tasimelteon Teva Pharmaceuticals, Inc. 2022-12-29
43068-0220-01 30 CAPSULE in 1 BOTTLE (43068-220-01) Hetlioz Vanda Pharmaceuticals Inc. 2014-04-04
43068-0304-02 1 BOTTLE in 1 CARTON (43068-304-02) / 48 mL in 1 BOTTLE Hetlioz LQ Vanda Pharmaceuticals Inc. 2020-12-10
43068-0304-06 1 BOTTLE in 1 CARTON (43068-304-06) / 158 mL in 1 BOTTLE Hetlioz LQ Vanda Pharmaceuticals Inc. 2020-12-10
60505-4665-03 30 CAPSULE in 1 BOTTLE (60505-4665-3) Tasimelteon Apotex Corp. 2024-01-05
60505-4665-09 90 CAPSULE in 1 BOTTLE (60505-4665-9) Tasimelteon Apotex Corp. 2024-01-05
69238-2548-03 30 CAPSULE in 1 BOTTLE (69238-2548-3) Tasimelteon Amneal Pharmaceuticals NY LLC 2023-02-24
Observed labelers: Vanda Pharmaceuticals Inc. (3) · Apotex Corp. (2) · Amneal Pharmaceuticals NY LLC (1) · Teva Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.